Seeking Alpha

Intrexon trades higher after Medistem acquisition

  • Shares of Intrexon (XON +1.4%) look to close modestly higher after the company's $26M deal for California-based Medistem (MEDS +47.7%) which develops Endometrial Regenerative Cells.
  • XON says the cells "have the potential to provide treatments for conditions such as cancer, wound healing, and cardiovascular disease," when combined with integrated synthetic biology platforms.
  • More specifically, XON plans to "develop two powerful classes of clinical products": Engineered stem cells for "therapeutic delivery of secreted proteins" and for "producing exosomes."
  • MEDS shareholders are getting $0.27 in cash and "$1.08 worth of XON common stock." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|